Background: The Fernand-Widal triad (FWT) is the association of non-allergic intrinsic asthma, nasal polyposis and sensitivity to Aspirin®. The aim of this paper is to describe the possibility of ocular complications, which we found in 3 cases: in 1 case due to the FWT itself and in the other 2 as a result of corticosteroid treatment. Methods: Three cases of the FWT with ocular complications were studied, and the pertinent literature was reviewed. Results: No previous description of ocular involvement in individuals with FWT was found in the literature. In the first case, episodes of orbital cellulitis due to superinfected nasal polyposis were found as a complication produced by the disease. In the other 2 cases, corticosteroid treatment created complications: ocular hypertension in both cases and bilateral subcapsular cataracts in 1 case. Conclusions: Although not rare, the diagnosis of the FWT is often missed. This perhaps explains why no report of ocular complications has yet been published in the literature. Because of the serious clinical consequences, physicians involved in the treatment of these patients should be aware of this diagnosis.

Keywords:
Fernand-Widal triad, Asthma, Nasal polyposis, Acetylsalicylic acid, Eye, Ocular cellulitis, Ocular hypertension, Glaucoma
1.
Widal F, Abrami P, Lermoyez J: Anaphylaxie et idiosyncrasie (Anaphylaxis and idiosyncrasy). Presses Méd 1922;18:189–193.
2.
Hirschberg SR: Mitteilung über einen Fall von Nebenwirkung des Aspirins (Case report about an aspirin side effect). Dtsch Med Wochenschr 1902;28:416.
3.
Gilbert GB: Unusual idiosyncrasy to aspirin. JAMA 1911;6:1262.
4.
Reed EN: Idiosyncrasy to aspirin (acetyl-salicylic acid). JAMA 1914;12:733.
5.
Cooke RA: Allergy in drug idiosyncrasy. JAMA 1919;23:759.
6.
Sonneville A: Current synthetic notions on aspirin induced asthma. Biomed Pharmacother 1999;53:312–314.
7.
McFadden ER: Asthma; in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison’s Principles of Internal Medicine, ed 13. New York, McGraw-Hill, 1994, pp 1167–1172.
8.
Szczeklik A, Gryglewski RJ, Czeniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;i:67–69.
9.
Lee TH: Mechanisms of aspirin sensitivity. Am Rev Respir Dis 1992;145:S34–36.
10.
O’Byrne PM, Israel E, Drazen JM: Antileukotrienes in the treatment of asthma. Ann Intern Med 1997;127:472–480.
11.
Sampson A, Holgate S: Leukotriene modifiers in the treatment of asthma. Br Med J 1998;316:1257–1258.
12.
Markham A, Jarvis B: Inhaled saleterol/fluticasone propionate combination: A review of its use in persistent asthma. Drugs 2000;60:1207–1233.
13.
Jarvis B, Markham A: Montelukast: A review of its therapeutic potential in persistent asthma. Drugs 2000;59:891–928.
14.
Lipworth BJ: Sytemic adverse effect of inhaled corticosteroid therapy: A systemic review and meta-analysis. Arch Intern Med 1999;159:941–955.
15.
Mitchell P, Cumming RG, Mackey DA: Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999;106:2301–2306.
16.
Opatowski I, Feldman RM, Gross R, Feldman ST: Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995;102:177–179.
17.
Armaly MF: Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 1965;4:187–197.
18.
Armaly MF: Effect of corticosteroids on intra-ocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482–491.
19.
Becker B: Diabetes mellitus and primary open angle glaucoma: The 27th Edward Jackson Memorial Lecture. Am J Ophthalmol 1971;71:1–16.
20.
Becker B, Hahn KA: Topical corticosteroids and heredity in primary open angle glaucoma. Am J Ophthalmol 1964;57:543–551.
21.
Podos, SM, Becker B, Morton WR: High myopia and primary open angle glaucoma. Am J Ophthalmol 1966;62:1039–1043.
22.
Gaston H, Absolon MJ, Thurtle OA, Sattar MA: Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983;67:487–490.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.